BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Bryan P,Schneider

第一单位： Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.

作者： Bryan P,Schneider ^[1] ; Guanglong,Jiang ^[1] ; Tarah J,Ballinger ^[1] ; Fei,Shen ^[1] ; Christopher,Chitambar ^[2] ; Rita,Nanda ^[3] ; Carla,Falkson ^[4] ; Filipa C,Lynce ^[5] ; Christopher,Gallagher ^[5] ; Claudine,Isaacs ^[5] ; Marcelo,Blaya ^[6] ; Elisavet,Paplomata ^[7] ; Radhika,Walling ^[8] ; Karen,Daily ^[9] ; Reshma,Mahtani ^[10] ; Michael A,Thompson ^[11] ; Robert,Graham ^[12] ; Maureen E,Cooper ^[13] ; Dean C,Pavlick ^[13] ; Lee A,Albacker ^[13] ; Jeffrey,Gregg ^[13] ; Jeffrey P,Solzak ^[14] ; Yu-Hsiang,Chen ^[1] ; Casey L,Bales ^[1] ; Erica,Cantor ^[1] ; Bradley A,Hancock ^[1] ; Nawal,Kassem ^[1] ; Paul,Helft ^[1] ; Bert,O'Neil ^[1] ; Anna Maria V,Storniolo ^[1] ; Sunil,Badve ^[1] ; Kathy D,Miller ^[1] ; Milan,Radovich ^[1]

作者单位： Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN. ^[1] Medical College of Wisconsin, Milwaukee, WI. ^[2] University of Chicago, Chicago, IL. ^[3] University of Alabama at Birmingham, Birmingham, AL. ^[4] Georgetown University, Washington, DC. ^[5] Memorial Healthcare System, Hollywood, FL. ^[6] Winship Cancer Institute of Emory University, Atlanta, GA. ^[7] Community Regional Cancer Care, Indianapolis, IN. ^[8] University of Florida, Gainesville, FL. ^[9] Sylvester Comprehensive Cancer Center, Deerfield Beach, FL. ^[10] Advocate Aurora Health, Milwaukee, WI. ^[11] Erlanger Health System, Chattanooga, TN. ^[12] Foundation Medicine Inc, Cambridge, MA. ^[13] University of California at Davis, Sacramento, CA. ^[14]